figshare: https://api.figshare.com/v2/articles/28823159
version: 2.1.0
datasets:
  beataml:
    description: Beat acute myeloid leukemia (BeatAML) focuses on acute myeloid leukemia tumor data. Data includes drug response, proteomics, and transcriptomics datasets.
    references:
      - citation: Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850-864.e9.
        doi: https://doi.org/10.1016/j.ccell.2022.07.002
      - citation: Pino JC, Posso C, Joshi SK, et al. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia. Cell Rep Med. 2024;5(1):101359.
        doi: https://doi.org/10.1016/j.xcrm.2023.101359
    modalities:
      - sample
      - transcriptomics
      - mutations
      - proteomics
      - drug
      - drug descriptor
      - experiments

  bladderpdo:
    description: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Data includes transcriptomics, mutations, copy number, and drug response data.
    references:
      - citation: Suk Hyung Lee, Wenhuo Hu, Justin T. Matulay, et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018;173(2):515-528.e17.
        doi: https://doi.org/10.1016/j.cell.2018.03.017
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number
      - drug
      - drug descriptor
      - experiments

  ccle:
    description: Cancer Cell Line Encyclopedia (CCLE).
    references:
      - citation: Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
        doi: https://doi.org/10.1038/nature11003
    modalities:
      - sample
      - transcriptomics
      - proteomics
      - mutations
      - copy number
      - drug
      - drug descriptor
      - experiments

  cptac:
    description: The Clinical Proteomic Tumor Analysis Consortium (CPTAC) project is a collaborative network funded by the National Cancer Institute (NCI) focused on improving our understanding of cancer biology through the integration of transcriptomic, proteomic, and genomic data.
    references:
      - citation: Lindgren CM, Adams DW, Kimball B, et al. Simplified and Unified Access to Cancer Proteogenomic Data. J Proteome Res. 2021;20(4):1902-1910.
        doi: https://doi.org/10.1021/acs.jproteome.0c00919
    modalities:
      - sample
      - transcriptomics
      - proteomics
      - mutations
      - copy number

  ctrpv2:
    description: Cancer Therapeutics Response Portal version 2 (CTRPv2)
    references:
      - citation: Rees MG, Seashore-Ludlow B, Cheah JH, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109-116.
        doi: https://doi.org/10.1038/nchembio.1986
      - citation: Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov. 2015;5(11):1210-1223.
        doi: https://doi.org/10.1158/2159-8290.CD-15-0235
      - citation: Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154(5):1151-1161.
        doi: https://doi.org/10.1016/j.cell.2013.08.003
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number
      - drug
      - drug descriptor
      - experiments

  fimm:
    description: Institute for Molecular Medicine Finland (FIMM) dataset.
    references:
      - citation: Mpindi JP, Yadav B, Östling P, et al. Consistency in drug response profiling. Nature. 2016;540(7631):E5-E6.
        doi: https://doi.org/10.1038/nature20171
      - citation: Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416-1429.
        doi: https://doi.org/10.1158/2159-8290.CD-13-0350
    modalities:
      - sample
      - transcriptomics
      - drug
      - drug descriptor
      - experiments

  hcmi:
    description: Human Cancer Models Initiative (HCMI) encompasses numerous cancer types and includes cell line, organoid, and tumor data.
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number

  mpnst:
    description: Malignant Peripheral Nerve Sheath Tumor is a rare, aggressive sarcoma that affects peripheral nerves throughout the body.
    references:
      - citation: Dehner C, Moon CI, Zhang X, et al. Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight. 2021;6(6):e146351.
        doi: https://doi.org/10.1172/jci.insight.146351
    modalities:
      - sample
      - transcriptomics
      - proteomics
      - mutations
      - copy number
      - drug
      - drug descriptor
      - experiments

  mpnstpdx:
    description: Patient-derived xenograft data for MPNST.
    modalities:
      - sample
      - transcriptomics
      - drug
      - drug descriptor
      - experiments

  nci60:
    description: National Cancer Institute 60.
    references:
      - citation: Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813-823.
        doi: https://doi.org/10.1038/nrc1951
    modalities:
      - sample
      - transcriptomics
      - mutations
      - proteomics
      - drug
      - drug descriptor
      - experiments

  pancpdo:
    description: Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Data includes transcriptomics, mutations, copy number, and drug response data.
    references:
      - citation: Tiriac H, Belleau P, Engle DD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8(9):1112-1129.
        doi: https://doi.org/10.1158/2159-8290.CD-18-0349
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number
      - drug
      - drug descriptor
      - experiments

  prism:
    description: Profiling Relative Inhibition Simultaneously in Mixtures.
    references:
      - citation: Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1(2):235-248.
        doi: https://doi.org/10.1038/s43018-019-0018-6
      - citation: Yu C, Mannan AM, Yvone GM, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016;34(4):419-423.
        doi: https://doi.org/10.1038/nbt.3460
    modalities:
      - sample
      - transcriptomics
      - drug
      - drug descriptor
      - experiments

  sarcpdo:
    description: The landscape of drug sensitivity and resistance in sarcoma. Data includes transcriptomics, mutations, and drug response data.
    references:
      - citation: Al Shihabi A, Tebon PJ, Nguyen HTL, et al. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024;31(10):1524-1542.e4.
        doi: https://doi.org/10.1016/j.stem.2024.08.010
    modalities:
      - sample
      - transcriptomics
      - mutations
      - drug
      - drug descriptor
      - experiments

  crcpdo:
    description: Living organoid biobank of colorectal cancer patients.
    references:
      - citation: van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933-945.
        doi: https://doi.org/10.1016/j.cell.2015.03.053
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number
      - drug
      - drug descriptor

  liverpdo:
    description: Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
    references:
      - citation: Ji S, Feng L, Fu Z, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med. 2023;15(706):eadg3358.
        doi: https://doi.org/10.1126/scitranslmed.adg3358
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number
      - drug
      - drug descriptor

  novartispdx:
    description: Patient-derived tumor xenografts for drug response prediction.
    references:
      - citation: Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318–1325.
        doi: https://doi.org/10.1038/nm.3954
    modalities:
      - sample
      - transcriptomics
      - mutations
      - copy number
      - drug
      - drug descriptor

  gcsi:
    description: The Genentech Cell Line Screening Initiative (gCSI)
    references:
      - citation: Haverty PM, Lin E, Tan J, et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature. 2016;533(7603):333–337.
        doi: https://doi.org/10.1038/nature17987
      - citation: Klijn C, Durinck S, Stawiski EW, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33(3):306–312.
        doi: https://doi.org/10.1038/nbt.3080
    modalities:
      - sample
      - transcriptomics
      - proteomics
      - mutations
      - copy number
      - drug
      - drug descriptor

  gdscv1:
    description: Genomics of Drug Sensitivity in Cancer version 1 (GDSCv1)
    references:
      - citation: Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570–575.
        doi: https://doi.org/10.1038/nature11005
      - citation: Iorio F, Knijnenburg TA, Vis DJ, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016;166(3):740–754.
        doi: https://doi.org/10.1016/j.cell.2016.06.017
      - citation: Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–D961.
        doi: https://doi.org/10.1093/nar/gks1111
    modalities:
      - sample
      - transcriptomics
      - proteomics
      - mutations
      - copy number
      - drug
      - drug descriptor

  gdscv2:
    description: Genomics of Drug Sensitivity in Cancer version 2 (GDSCv2)
    references:
      - citation: Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570–575.
        doi: https://doi.org/10.1038/nature11005
      - citation: Iorio F, Knijnenburg TA, Vis DJ, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016;166(3):740–754.
        doi: https://doi.org/10.1016/j.cell.2016.06.017
      - citation: Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–D961.
        doi: https://doi.org/10.1093/nar/gks1111
    modalities:
      - sample
      - transcriptomics
      - proteomics
      - mutations
      - copy number
      - drug
      - drug descriptor
